In the UK, there are specific NHS criteria: Semaglutide 2.4mg (Wegovy) : NICE technology appraisal TA875 recommends this only within specialist weight management services and for a maximum of 2 years on the NHS [2] Liraglutide 3.0mg (Saxenda) : NICE technology appraisal TA664 specifies that treatment should only continue beyond 12 weeks if you've lost at least 5% of your initial body weight Clinical trials have demonstrated that most people regain weight after stopping GLP-1 medications
Also noted in Table 2 , several GLP-1 RAs have demonstrated favorable effects on secondary kidney outcomes
You can think of them as tiny messengers that travel through your body, giving your cells specific instructions
Adults experiencing fatigue, slow recovery, poor sleep, or age-related decline may benefit
Most reports describe headaches appearing within the first two to four weeks of starting the medication, with severity varying from mild tension-type headaches to debilitating migraines requiring medication intervention
Gastroparesis patients endure persistent nausea, severe abdominal cramping, repeated vomiting episodes disrupting daily activities, and malnutrition from inability to properly digest food